Cipla receives final approval for the generic version of Somatuline Depot Injection
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (Lanreotide) Injection
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Lupin updates on shipment of Mirabegron ER Tablets
Subscribe To Our Newsletter & Stay Updated